Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate |
Kizilirmak, Filiz
(Department of Cardiology, Medipol University Hospital)
Gunes, Haci Murat (Department of Cardiology, Medipol University Hospital) Guler, Ekrem (Department of Cardiology, Medipol University Hospital) Demir, Gultekin Gunhan (Department of Cardiology, Medipol University Hospital) Karaca, Oguz (Department of Cardiology, Medipol University Hospital) Canpolat, Habibe Gamze (Department of Cardiology, Medipol University Hospital) |
1 | van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27. DOI |
2 | Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5. DOI |
3 | Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (dabigatran etexilate) package insert. Ridgefield, CT: Author; 2011. |
4 | Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. DOI |
5 | Lal Y, Van Heukelom J. Dabigatran: a cause of hematologic emergency. Am J Med Sci 2013;346:190-3. DOI |
6 | Nyby S, Hennes O. Fatal bleeding diarrhoea during dabigatran etexilate therapy. Ugeskr Laeger 2014;176. pii: V09140482. |
7 | Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother 2012;46:e18. DOI |
8 | Barton CA, McMillian WD, Raza SS, Keller RE. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy 2012;32:e103-7. DOI |
9 | Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72. DOI |
10 | Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95. DOI |
11 | Kernan L, Ito S, Shirazi F, Boesen K. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila) 2012;50:571-3. DOI |
12 | Lindahl TL, Baghaei F, Blixter IF, et al; Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8. DOI |
13 | Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985-97. DOI |
14 | Kim J, Yadava M, An IC, et al. Coagulopathy and extremely elevated PT/INR after dabigatran etexilate use in a patient with end-stage renal disease. Case Rep Med 2013;2013:131395. |
![]() |